Good morning and welcome to Markets Desk, your midday read on what's moving and why.
Berkshire Hathaway is finally putting its nearly four hundred billion dollar cash pile to work, and the name it chose is itself. The conglomerate has resumed buying back its own shares after years of letting that reserve build, a move that signals Buffett sees Berkshire as undervalued but leaves some investors wanting a bolder deployment into new positions.
Shifting to the macro picture around artificial intelligence, Apollo's chief economist Torsten Slok is raising a pointed concern — that AI profits right now are largely being funded by investor capital rather than genuine customer revenue. The implication is sobering: the technology may be delivering real productivity gains in parts of the economy, but the equity valuations built around it could still constitute a bubble, just one that arrives through a different door than most expect.
And on the restructuring front, aTyr Pharma is cutting sixty percent of its workforce as it narrows its focus entirely on advancing Efzofitimod into phase three trials for interstitial lung disease. The company reported a narrower net loss in the second quarter of two thousand twenty six, and management is clearly betting that concentrating resources on a single lead candidate is the cleaner path to value creation.
That's the tape. Markets Desk, signing off the floor.
